BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.
dc.contributor.author | Nyberg, Tommy | |
dc.contributor.author | Tischkowitz, Marc | |
dc.contributor.author | Antoniou, Antonis | |
dc.date.accessioned | 2021-12-14T00:31:09Z | |
dc.date.available | 2021-12-14T00:31:09Z | |
dc.date.issued | 2021-12-28 | |
dc.identifier.issn | 0007-0920 | |
dc.identifier.uri | https://www.repository.cam.ac.uk/handle/1810/331376 | |
dc.description.abstract | BACKGROUND: BRCA1 and BRCA2 pathogenic variants (PVs) are associated with prostate cancer (PCa) risk, but a wide range of relative risks (RRs) has been reported. METHODS: We systematically searched PubMed, Embase, MEDLINE and Cochrane Library in June 2021 for studies that estimated PCa RRs for male BRCA1/2 carriers, with no time or language restrictions. The literature search identified 27 studies (BRCA1: n = 20, BRCA2: n = 21). RESULTS: The heterogeneity between the published estimates was high (BRCA1: I2 = 30%, BRCA2: I2 = 83%); this could partly be explained by selection for age, family history or aggressive disease, and study-level differences in ethnicity composition, use of historical controls, and location of PVs within BRCA2. The pooled RRs were 2.08 (95% CI 1.38-3.12) for Ashkenazi Jewish BRCA2 carriers, 4.35 (95% CI 3.50-5.41) for non-Ashkenazi European ancestry BRCA2 carriers, and 1.18 (95% CI 0.95-1.47) for BRCA1 carriers. At ages <65 years, the RRs were 7.14 (95% CI 5.33-9.56) for non-Ashkenazi European ancestry BRCA2 and 1.78 (95% CI 1.09-2.91) for BRCA1 carriers. CONCLUSIONS: These PCa risk estimates will assist in guiding clinical management. The study-level subgroup analyses indicate that risks may be modified by age and ethnicity, and for BRCA2 carriers by PV location within the gene, which may guide future risk-estimation studies. | |
dc.description.sponsorship | Cancer Research UK [grants C12292/A20861, C12292/A22820 and PPRPGM-Nov20\100002]; supported by the National Institute for Health Research Cambridge Biomedical Research Centre. | |
dc.publisher | Springer Science and Business Media LLC | |
dc.rights | All Rights Reserved | |
dc.rights.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
dc.title | BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis. | |
dc.type | Article | |
dc.publisher.department | Mrc Biostatistics Unit | |
dc.date.updated | 2021-12-10T18:18:54Z | |
prism.publicationName | Br J Cancer | |
dc.identifier.doi | 10.17863/CAM.78827 | |
dcterms.dateAccepted | 2021-12-10 | |
rioxxterms.versionofrecord | 10.1038/s41416-021-01675-5 | |
rioxxterms.version | AM | |
dc.contributor.orcid | Nyberg, Tommy [0000-0002-9436-0626] | |
dc.contributor.orcid | Tischkowitz, Marc [0000-0002-7880-0628] | |
dc.contributor.orcid | Antoniou, Antonis [0000-0001-9223-3116] | |
dc.identifier.eissn | 1532-1827 | |
rioxxterms.type | Journal Article/Review | |
pubs.funder-project-id | Cancer Research UK (S_3380) | |
pubs.funder-project-id | Cancer Research UK (C12292/A22820) | |
pubs.funder-project-id | Cancer Research UK (20861) | |
cam.issuedOnline | 2021-12-28 | |
cam.orpheus.success | Tue Feb 01 19:02:28 GMT 2022 - Embargo updated | * |
cam.depositDate | 2021-12-10 | |
pubs.licence-identifier | apollo-deposit-licence-2-1 | |
pubs.licence-display-name | Apollo Repository Deposit Licence Agreement | |
rioxxterms.freetoread.startdate | 2022-06-28 |
Files in this item
This item appears in the following Collection(s)
-
Cambridge University Research Outputs
Research outputs of the University of Cambridge